Kosmo Online
Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million... The post Telix and Regeneron Announce Strategic Radiopharma Collaboration appeared first on Kosmo Digital .
Go to News Site